EligibleTrials

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Recruiting · NCT07398417 · Interventional (participants receive a specific treatment) · Lead sponsor: Axsome Therapeutics, Inc.

View the official record on ClinicalTrials.gov →
Fibromyalgia

Interventions studied

AXS-14 (Esreboxetine)Placebo

What this trial is about

The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

53 locations listed across 21 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.